The Law Offices of Frank R. Cruz filed the complaint alleging that Erasca misled shareholders regarding the integrity of its ERAS-0015 preclinical data. According to the filing, the company relied on improper comparisons to competitor RevMed, potentially infringing on patent and trade secret protections. These omissions allegedly rendered the company’s public statements about its operational outlook materially misleading throughout the specified sixteen-month period.

Investors who purchased shares during this timeframe and suffered financial losses are eligible to seek lead plaintiff status. While those who choose not to act will remain absent class members, the deadline for formal participation is strictly set for August 10, 2026. Interested parties may contact the firm at 310-914-5007 or via their website to discuss legal rights and potential recovery options.